雷美替胺

雷美替胺
臨床資料
商品名（英語：Drug nomenclature）	Rozerem, others
其他名稱	TAK-375
AHFS/Drugs.com	Monograph
MedlinePlus	a605038
核准狀況	美 DailyMed: Ramelteon;
依賴性	低
給藥途徑	口服
ATC碼	N05CH02 (WHO) ;
法律規範狀態
法律規範	美：處方藥（℞-only）;
藥物動力學數據
生物利用度	1.8%
血漿蛋白結合率	82%（大多為白蛋白）
藥物代謝	肝（CYP1A2，少部分由CYP2C（英語：CYP2C）與CYP3A4代謝）
代謝產物	M-II（活性代謝產物）
生物半衰期	雷美替胺：1–2.6小時; M-II：2–5小時
排泄途徑	尿液84%; 糞便4%
識別資訊
	IUPAC命名法 (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]; furan-8-yl)ethyl]propionamide; ;
CAS號	196597-26-9
PubChem CID	208902;
IUPHAR/BPS	1356;
DrugBank	DB00980 ;
ChemSpider	9033484 ;
UNII	901AS54I69;
KEGG	D02689 ;
ChEMBL	ChEMBL133775 ;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID6045951 ;
ECHA InfoCard	100.215.666
化學資訊
化學式	C16H21NO2
摩爾質量	259.35 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES CCC(=O)NCC[C@@H]1CCc2ccc3c(c21)CCO3;
	InChI InChI=1S/C16H21NO2/c1-2-15(18)17-9-7-12-4-3-11-5-6-14-13(16(11)12)8-10-19-14/h5-6,12H,2-4,7-10H2,1H3,(H,17,18)/t12-/m1/s1 ; Key:YLXDSYKOBKBWJQ-GFCCVEGCSA-N ;

雷美替胺，商品名柔速瑞（Rozerem），是可治療因難以入睡而失眠的褪黑激素受體激動劑（英語：melatonin agonist）。^[2]^[4]它可減少入睡所需的時間，但臨床益處較少。^[5]它是口服藥。^[2]

雷美替胺的副作用包括昏睡、頭暈、疲勞、噁心、失眠加劇、激素水平改變。^[2]它是褪黑激素的結構類似物，也是褪黑激素受體1A（英語：MT1 receptor）和褪黑激素受體1B（英語：MT2 receptor）的選擇性激動劑。^[2]雷美替胺的生物半衰期和藥效持續時間都比褪黑激素長。^[6]它不是苯二氮䓬類或非苯二氮䓬類藥物，不作用於GABA受體，有獨特的作用機制。^[2]^[7]

雷美替胺於2002年發現，^[8]2005年獲批用於醫藥。^[9]

參考資料

^ Kim, HK; Yang, KI. Melatonin and melatonergic drugs in sleep disorders.. Translational and clinical pharmacology. December 2022, 30 (4): 163–171. PMC 9810491  . PMID 36632077. doi:10.12793/tcp.2022.30.e21  .
^ ^2.00 ^2.01 ^2.02 ^2.03 ^2.04 ^2.05 ^2.06 ^2.07 ^2.08 ^2.09 ^2.10 ^2.11 ^2.12 ^2.13 Rozerem- ramelteon tablet, film coated. DailyMed. 2018-12-28 [2020-04-13]. （原始內容存檔於2021-03-26）.
^ Karim A, Tolbert D, Cao C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. Journal of Clinical Pharmacology. February 2006, 46 (2): 140–148. PMID 16432265. S2CID 38171735. doi:10.1177/0091270005283461.
^ Neubauer DN. A review of ramelteon in the treatment of sleep disorders. Neuropsychiatric Disease and Treatment. February 2008, 4 (1): 69–79. PMC 2515902  . PMID 18728808. doi:10.2147/ndt.s483  .
^ Kuriyama A, Honda M, Hayashino Y. Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. Sleep Medicine. April 2014, 15 (4): 385–392. PMID 24656909. doi:10.1016/j.sleep.2013.11.788.
^ Hardeland R, Poeggeler B, Srinivasan V, Trakht I, Pandi-Perumal SR, Cardinali DP. Melatonergic drugs in clinical practice. Arzneimittel-Forschung. 2008, 58 (1): 1–10. PMID 18368944. S2CID 38857779. doi:10.1055/s-0031-1296459.
^ Atkin T, Comai S, Gobbi G. Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery. Pharmacological Reviews. April 2018, 70 (2): 197–245. PMID 29487083. S2CID 3578916. doi:10.1124/pr.117.014381  .
^ Uchikawa O, Fukatsu K, Tokunoh R, Kawada M, Matsumoto K, Imai Y, et al. Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists. Journal of Medicinal Chemistry. September 2002, 45 (19): 4222–4239. PMID 12213063. doi:10.1021/jm0201159.
^ Drug Approval Package: Rozerem (Ramelteon) NDA #021782. U.S. Food and Drug Administration (FDA). 2005-10-20 [2020-04-13]. （原始內容存檔於2021-03-31）.

外部連結

Ramelteon. Drug Information Portal. U.S. National Library of Medicine. [2024-01-26]. （原始內容存檔於2019-06-28）.

[Yang2022-1] Kim, HK; Yang, KI. Melatonin and melatonergic drugs in sleep disorders.. Translational and clinical pharmacology. December 2022, 30 (4): 163–171. PMC 9810491  . PMID 36632077. doi:10.12793/tcp.2022.30.e21  .

[Rozerem_FDA_label-2] 2.00 ^2.01 ^2.02 ^2.03 ^2.04 ^2.05 ^2.06 ^2.07 ^2.08 ^2.09 ^2.10 ^2.11 ^2.12 ^2.13 Rozerem- ramelteon tablet, film coated. DailyMed. 2018-12-28 [2020-04-13]. （原始內容存檔於2021-03-26）.

[3] Karim A, Tolbert D, Cao C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. Journal of Clinical Pharmacology. February 2006, 46 (2): 140–148. PMID 16432265. S2CID 38171735. doi:10.1177/0091270005283461.

[pmid18728808-4] Neubauer DN. A review of ramelteon in the treatment of sleep disorders. Neuropsychiatric Disease and Treatment. February 2008, 4 (1): 69–79. PMC 2515902  . PMID 18728808. doi:10.2147/ndt.s483  .

[pmid24656909-5] Kuriyama A, Honda M, Hayashino Y. Ramelteon for the treatment of insomnia in adults: a systematic review and meta-analysis. Sleep Medicine. April 2014, 15 (4): 385–392. PMID 24656909. doi:10.1016/j.sleep.2013.11.788.

[pmid18368944-6] Hardeland R, Poeggeler B, Srinivasan V, Trakht I, Pandi-Perumal SR, Cardinali DP. Melatonergic drugs in clinical practice. Arzneimittel-Forschung. 2008, 58 (1): 1–10. PMID 18368944. S2CID 38857779. doi:10.1055/s-0031-1296459.

[pmid29487083-7] Atkin T, Comai S, Gobbi G. Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery. Pharmacological Reviews. April 2018, 70 (2): 197–245. PMID 29487083. S2CID 3578916. doi:10.1124/pr.117.014381  .

[pmid12213063-8] Uchikawa O, Fukatsu K, Tokunoh R, Kawada M, Matsumoto K, Imai Y, et al. Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists. Journal of Medicinal Chemistry. September 2002, 45 (19): 4222–4239. PMID 12213063. doi:10.1021/jm0201159.

[FDA2005-9] Drug Approval Package: Rozerem (Ramelteon) NDA #021782. U.S. Food and Drug Administration (FDA). 2005-10-20 [2020-04-13]. （原始內容存檔於2021-03-31）.

[2]

[4]

[5]

[1]

[3]

[6]

[7]

[8]

[9]